Analysts expect that Theravance Biopharma Inc (NASDAQ:TBPH) will post ($1.15) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Theravance Biopharma’s earnings, with the highest EPS estimate coming in at ($1.14) and the lowest estimate coming in at ($1.16). Theravance Biopharma reported earnings per share of ($1.36) during the same quarter last year, which would suggest a positive year-over-year growth rate of 15.4%. The firm is scheduled to report its next quarterly earnings results on Monday, February 26th.
On average, analysts expect that Theravance Biopharma will report full-year earnings of ($4.84) per share for the current fiscal year, with EPS estimates ranging from ($5.01) to ($4.49). For the next financial year, analysts expect that the company will post earnings of ($4.44) per share, with EPS estimates ranging from ($4.75) to ($4.17). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Theravance Biopharma.
TBPH has been the subject of several recent analyst reports. ValuEngine lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Cantor Fitzgerald restated a “buy” rating and set a $55.00 target price on shares of Theravance Biopharma in a research report on Tuesday, November 7th. Needham & Company LLC reaffirmed a “buy” rating on shares of Theravance Biopharma in a research note on Tuesday, December 5th. Zacks Investment Research raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday, September 19th. Finally, Robert W. Baird reaffirmed a “sell” rating and set a $22.00 price target on shares of Theravance Biopharma in a research note on Wednesday, November 1st. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. Theravance Biopharma has a consensus rating of “Hold” and a consensus target price of $41.86.
Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its holdings in Theravance Biopharma by 3.6% in the 2nd quarter. BlackRock Inc. now owns 3,638,838 shares of the biopharmaceutical company’s stock valued at $144,972,000 after acquiring an additional 126,393 shares during the last quarter. Vanguard Group Inc. raised its holdings in Theravance Biopharma by 3.8% in the 2nd quarter. Vanguard Group Inc. now owns 3,197,277 shares of the biopharmaceutical company’s stock valued at $127,379,000 after acquiring an additional 116,981 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Theravance Biopharma by 174.8% in the 2nd quarter. Wells Fargo & Company MN now owns 88,688 shares of the biopharmaceutical company’s stock valued at $3,533,000 after acquiring an additional 56,418 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in Theravance Biopharma in the 2nd quarter valued at about $1,235,000. Finally, Northern Trust Corp grew its stake in shares of Theravance Biopharma by 6.1% in the 2nd quarter. Northern Trust Corp now owns 530,049 shares of the biopharmaceutical company’s stock valued at $21,117,000 after buying an additional 30,611 shares during the period. 86.02% of the stock is owned by hedge funds and other institutional investors.
Shares of Theravance Biopharma (TBPH) traded down $0.13 during trading hours on Thursday, hitting $27.94. The company’s stock had a trading volume of 153,800 shares, compared to its average volume of 143,050. Theravance Biopharma has a fifty-two week low of $23.15 and a fifty-two week high of $43.44. The stock has a market capitalization of $1,510.00, a price-to-earnings ratio of -5.41 and a beta of 2.35. The company has a quick ratio of 7.21, a current ratio of 7.53 and a debt-to-equity ratio of 1.21.
TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Anticipate Theravance Biopharma Inc (TBPH) to Post -$1.15 Earnings Per Share” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/04/zacks-brokerages-anticipate-theravance-biopharma-inc-tbph-to-post-1-15-earnings-per-share.html.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.